Economics, Pharmaceutical
"Economics, Pharmaceutical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Economic aspects of the fields of pharmacy and pharmacology as they apply to the development and study of medical economics in rational drug therapy and the impact of pharmaceuticals on the cost of medical care. Pharmaceutical economics also includes the economic considerations of the pharmaceutical care delivery system and in drug prescribing, particularly of cost-benefit values. (From J Res Pharm Econ 1989;1(1); PharmacoEcon 1992;1(1))
| Descriptor ID |
D017850
|
| MeSH Number(s) |
N03.219.390
|
| Concept/Terms |
Pharmacy Economics- Pharmacy Economics
- Economic, Pharmacy
- Economics, Pharmacy
- Pharmacy Economic
|
Below are MeSH descriptors whose meaning is more general than "Economics, Pharmaceutical".
Below are MeSH descriptors whose meaning is more specific than "Economics, Pharmaceutical".
This graph shows the total number of publications written about "Economics, Pharmaceutical" by people in this website by year, and whether "Economics, Pharmaceutical" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Economics, Pharmaceutical" by people in Profiles.
-
Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative. Pharmacoepidemiol Drug Saf. 2020 11; 29(11):1504-1513.
-
Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017 Sep; 26(9):1033-1039.
-
Cost-effectiveness analyses of osteoarthritis oral therapies: a systematic review. Appl Health Econ Health Policy. 2013 Dec; 11(6):593-618.
-
The cost-effectiveness of sertraline in the treatment of depression. Expert Opin Pharmacother. 2008 Oct; 9(14):2497-508.
-
The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis. Pharmacoeconomics. 2007; 25(8):649-64.
-
Economic evaluations in pain management: principles and methods. J Pain Palliat Care Pharmacother. 2006; 20(3):15-23.
-
Seniors with chronic health conditions and prescription drugs: benefits, wealth, and health. Value Health. 2004 Mar-Apr; 7(2):133-43.
-
The economics of venous thromboembolism prophylaxis: a primer for clinicians. Chest. 2003 Dec; 124(6 Suppl):393S-396S.